Investing in tomorrow's healthcare

Angels in MedCity supports BeamLine Diagnostics’ £650k investment round

BeamLine Diagnostics, developers of an innovative biopsy triaging system, founded by Dr. Liberty Foreman and Dr. Katherine Willetts, has closed a £650k investment round which was led by a syndicate of Angels in MedCity (AiMC) investors including the London Co-Investment Fund (LCIF).

The BeamLine Solas system, a biopsy training system, combines data analysis methods with commercially-available hardware to provide a rapid, accurate and cost-effective system for screening biopsies at the point of care. The system integrates with existing clinical workflows, does not require extensive staff retraining, and results from each biopsy are returned within a few seconds.

Solas enables biopsies to be simply screened at the bedside, identifying over half of healthy samples (based on current performance) with 99% certainty within minutes. This reduces the total number of samples sent to pathology, allowing for faster turnaround of the samples received and, overall, gives patients a better service, less stress and a greater peace of mind.

This new round of funding will help the company to facilitate further product development and deliver a “first in-clinic” trial.

Liberty Foreman, BeamLine Diagnostic CEO, said: “We are really excited to be starting the next phase of BeamLine and intiating our first in clinic trials. Being part of Angels in Medcity and other angel groups has offered us such diverse but related experience that has really accelerated our growth.”

Sarah Haywood, MedCity CEO, said: “The growth of BeamLine has been incredible for me to watch, having sponsored the start-up accelerator OneStart, where BeamLine was originally formed. Liberty Foreman is a golden triangle success story, having developed the know-how that underpins the technology during her PhD at UCL. BeamLine’s biopsy triaging system can identify healthy and benign tissue specimens within seconds, and is a solution to the complex and time-consuming analysis that puts a burden on labs and can delay diagnosis. I’m pleased that, once again, our community of investors are providing funding to enable a company to get to the next level of growth

Anthony Clarke, LBA CEO, comments: Better and quicker diagnoses undoubtedly lead to better patient outcomes, and the BeamLine Solas system has the ability to disrupt the way in which biopsy results are analysed and delivered.

Thursday, April 27, 2017 - 14:00

Become an Angels in MedCity investor

Become an investor >


Become an Angels in MedCity entrepreneur

Entrepreneurs >